An Open-label, Single Dose Pharmacokinetic Study Of Benefix (Nonacog Alfa, Recombinant Factor Ix) In Male Chinese Subjects With Hemophilia B
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2016
Price : $35 *
At a glance
- Drugs Nonacog alfa (Primary)
- Indications Haemophilia B
- Focus Pharmacokinetics
- Sponsors Pfizer
- 04 May 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 09 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Apr 2015 s reported by ClinicalTrials.gov.
- 09 Mar 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.